Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms

BioSante Pharmaceuticals431 enrolled

Overview

The purpose of this study is to determine the efficacy and safety of a topical estradiol gel for the treatment of hot flushes in postmenopausal women.

Estrogens are a group of hormones that play an important role in normal sexual and reproductive development in women. Estrogens serve many functions in the body. They stimulate oocyte maturation and endometrial growth, decrease bone resorption, initiate the development of secondary sex characteristics, maintain reproductive organs and glands, and affect the activity of the central nervous system. At menopause, the decrease in estrogen concentrations is often accompanied by vascular instability (hot flushes and night sweats), a rise in the incidence of heart disease, and an increasing rate of bone loss. Estrogen is available as an oral drug, a transdermal patch, or as a gel or lotion. Transdermal estrogen is preferable as compared to oral, since it avoids the first-pass metabolism in the liver. Since release of the WHI findings, current treatment recommendations are for the lowest effective dose for the shortest period of time to treat postmenopausal symptoms. Comparison: Three doses of a transdermal estradiol gel as compared to placebo for the treatment of vasomotor and vulvovaginal atrophy symptoms in postmenopausal women.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

431

Conditions

Hot Flashes

Interventions

estradiol gelDRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Postmenopausal women * serum estradiol level less than or equal to 20 pg per mL * serum FSH greater than 40 mIU per mL Exclusion Criteria: * Pathological cancer findings on screening * abnormal endometrium * serious hepatic, renal or cardiac disease

Outcomes

Primary Outcomes

Mean change from baseline in number of daily moderate to severe hot flushes.

Mean change from baseline in daily hot flush severity.

Mean change from baseline in vulvovaginal atrophy symptoms.

Secondary Outcomes

Percent change from baseline in daily moderate to severe hot flush rates over time.

Percent change from baseline in hot flush severity over time.

Proportion of subjects with fifty to one hundred percent reductions in daily moderate to severe hot flushes.

Proportion of subjects with fifty to one hundred percent reductions in hot flush severity

Mean change from baseline in subject vaginal health self assessment over time.

Mean change from baseline in physician assessment of vaginal atrophy.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.